Three percent diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses: A meta-analysis of the recent studies

Archives of Dermatological Research

Volumn 297, Issue 5, 2005, Pages 185-189

  Pirard, D ^a,b   Vereecken, P ^a   Melot C ^a   Heenen, M ^a  

^a ERASME HOSPITAL   (Belgium)

^b NONE   (Belgium)

Author keywords

Actinic keratosis; Diclofenac; Hyaluronan; Meta analysis

Indexed keywords

DICLOFENAC; HYALURONIC ACID; PLACEBO;

ACTINIC KERATOSIS; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG SCREENING; DRUG TARGETING; FOLLOW UP; GEL; HUMAN; INFORMATION RETRIEVAL; MAJOR CLINICAL STUDY; MEDLINE; PATIENT CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBLICATION; RISK ASSESSMENT; SCORING SYSTEM; SKIN BIOPSY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONIC ACID; CLINICAL TRIALS; DICLOFENAC; DOUBLE-BLIND METHOD; GELS; HUMANS; HYALURONIC ACID; KERATOSIS;

EID: 27744588722     PISSN: 03403696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00403-005-0601-9     Document Type: Article

References (28)

1. Adamson DJA, Frew D, Tatoud R et al (2002) Diclofebac antagonizes peroxisome proliferator-activated receptor-γ signalling. Mol Pharmacol 61:7-12
2. Alam CAS, Seed MP, Willoughby DA (1995) Angiostasis and vascular regression in chronic granulomatous inflammation induced by diclofenac in combination with hyaluronan in mice. J Pharm Pharmacol 47:407-411
3. Arrich J, Piribauer F, Mad P et al (2005) Intra-articular hyaluronic acid for the treatment of osteoarthritis of the knee: systematic review and meta-analysis. CMAJ 172:1039-1043
4. Brown MB, Mariott C, Martin GP (1995) A study of the transdermal drug delivery properties of hyaluronan. Round Table Series 40:53-71
5. Brown M, Jones S (2005) Hyaluronic acid: a unique topical vehicle for the localized delivery of drugs to the skin. J Eur Acad Dermatol Venereol 19:308-318
6. Buckman SY, Gresham A, Hale P et al (1998) COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 19:723-729
7. Burkhart CN, Burkhart CG (2002) Reassessment of topical diclofenac/hyaluronan gel for actinic keratoses. Int J Dermatol 41:371-373
8. Cabrera PV, Blanco G, Alaniz L et al (2004) CD44 and hyaluronic acid regulate in vivo iNOS expression and metalloproteinase activity in murine air-pouch inflammation. Inflamm Res 53:556-566
9. Dentener MA, Vernooy JH, Hendriks S et al (2005) Enhanced levels of hyaluronan in lung of patients with COPD: relationship with lung function and local inflammation. Tohrax 60:114-119
10. Dinehart SM (2000)The treatment of actinic keratoses. J Am Acad Dermatol 42:525-528
11. Gebauer K, Brown P, Varigos G (2003) Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Austr J Dermatol 44:40-43
12. Glogau RG (2000) The risk of progression to invasive disease. J Am Acad Dermatol 42:S23-S24
13. Hascall VC, Majors AK, De la Motte CA et al (2004) Intracellular hyaluronan; a new frontier for inflammation? Biochim Biophys Acta 1673:3-12
14. Jarvis B, Figgit DP (2003) Topical 3%diclofenac in a 2.5% hyaluronic acid gel. A review of its use in patients with actinic keratoses. Am J Clin Dermatol 4(3):203-213
15. Masferrer JL, Leahy KM, Koki AT et al (2000) Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60:1306-1311
16. McEwan LE, Smith JG (1997) Topical diclofenac/hyaluronic acid gel in the treatment of solar keratoses. Austr J Dermatol 38:187-189
17. Moore AR, Willoughby DA (1995) Hyaluronan as a drug delivery system for diclofenac: a hypothesis for mode of action. Int J Tissue React 17:153-156
18. INK4a tumor suppressor. Cancer Lett 176:205-214
19. Nawrat P, Surazynki A, Karna E et al (2005) The effect of hyaluronic acid on interleukin-1-induced deregulation of collagen metabolism in cultured human skin fibroblasts. Pharmacol Res 51:473-477
20. Nelson C, Rigel D, Smith S, Swanson N, Wolf J (2004) Phase IV, open-label assessment of the treatmentof actinic keratosis with 3%diclofenac sodium topical gel (Solaraze™). J Drugs Dermatol 3(4):401-407
21. Novaes AC, Schaiquevich P, Nasswetter G (2005) Multicenter study of hyaluronic acid obtained by biotechnology to evaluate clinical efficacy and safety in knee osteoarthritis. Int J Clin Pharmacol res 25:1-7
22. Pistorius A, martin M, Willershausen B et al (2005) The clinical application of hyaluronic acid in gingivitis therapy. Quintescence Int 36:531-538
23. Rivers JK, McLean DI (1997) An open study to assess the efficacy and safety of topical 3%diclofenac in a 2.5%hyaluronan acid gel for the treatment of actinic keratoses. Arch Dermatol 133:1239-1242
24. Rivers JK, Arlette J, Shear N, Guenther L, Carey W, Poulin Y (2002) Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 146:94-100
25. Silapunt S, Goldberg LH, Alam M (2003) Topical and light-based treatments for actinic keratoses. Sem Cut Med Surg 22(3):162-170
26. Spencer JM, Kahn SM, Jiang W et al (1995) Activated ras genes occur in human actinic keratoses, premalignant precursors to squamous cell carcinoma. Arch Dermatol 131:796-800
27. Weindl G, Schaller M, Schafer-Korting M et al (2004) Hyaluronic acid in the treatment and prevention of skin diseases: molecular biological, pharmaceutical and clinical aspects. Skin Pharmacol Physiol 17:207-213
28. Wolf JE, Taylor JR, Tschen E, Kang S (2001) Topical 3.0% diclofenac gel in the treatment of actinic keratoses. Int J Dermatol 40:709-713